Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

  1. Bidard, F.-C.
  2. Kaklamani, V.G.
  3. Neven, P.
  4. Streich, G.
  5. Montero, A.J.
  6. Forget, F.
  7. Mouret-Reynier, M.-A.
  8. Sohn, J.H.
  9. Taylor, D.
  10. Harnden, K.K.
  11. Khong, H.
  12. Kocsis, J.
  13. Dalenc, F.
  14. Dillon, P.M.
  15. Babu, S.
  16. Waters, S.
  17. Deleu, I.
  18. García Sáenz, J.A.
  19. Bria, E.
  20. Cazzaniga, M.
  21. Lu, J.
  22. Aftimos, P.
  23. Cortés, J.
  24. Liu, S.
  25. Tonini, G.
  26. Laurent, D.
  27. Habboubi, N.
  28. Conlan, M.G.
  29. Bardia, A.
  30. Mostra tots els autors/es +
Revista:
Journal of Clinical Oncology

ISSN: 1527-7755,  0732-183X

Any de publicació: 2022

Volum: 32

Tipus: Article

DOI: 10.1200/JCO.22.00338 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus